EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial resistance landscape and COVID-19 impact in Egypt, Iraq, Jordan, and Lebanon: A survey-based study and expert opinion

Abdul Rahman Bizri, Alia Abd El-Fattah, Hafez Mahmoud Bazaraa, Jamal Wadi Al Ramahi iD, Madonna Matar iD, Rana Abdulmahdi Nahi Ali, Rowan El Masry, Jihane Moussa, Ali Jamal Al Abbas, Mohamed Abdel Aziz

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0288550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Abdul Rahman Bizri und 9 weiteren Autor:innen. Beteiligte Einrichtung: National COVID-19 Vaccine Committee, American University of Beirut Medical Center, Beirut, Lebanon. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, COVID-19. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The objective of this study was to assess the antimicrobial resistance (AMR) landscape and the impact of COVID-19 on AMR in Egypt, Iraq, Jordan, and Lebanon, and to gather expert opinions on the barriers to the implementation of antimicrobial stewardship (AMS) initiatives in the region.

Methods

A cross-sectional questionnaire survey was used to assess the current AMR landscape, existing AMS initiatives, barriers to implementing AMS initiatives, and the impact of COVID-19 on AMR in the four countries.

Results

The survey was completed by 204 physicians from Egypt (n = 82), Lebanon (n = 49), Iraq (n = 43), and Jordan (n = 30). Previous antibiotic use and previous bacterial colonization were perceived as the most common risk factors for an increase in AMR. According to the survey, multidrug-resistant (MDR) gram-negative bacteria were most common in lower respiratory tract infections, and Klebsiella pneumoniae and Escherichia coli were the most commonly identified gram-negative bacteria in hospital-acquired infections. Only 14.8% of pediatric physicians and 28.6% of adult physicians reported that target pathogen genotyping and phenotyping were done in hospitals, and the most commonly reported reasons for the lack of testing were technological and resource constraints. These constraints, coupled with the scarcity and high cost of newer antibiotics, have been identified as the most significant barriers to the successful management of MDR gram-negative bacterial infections in the region. It was reported that the spectrum of activity and safety of the antibiotic, the site of infection, the presence of comorbidities, and published guidelines and local antibiograms determined the choice of empirical antibiotic therapy for patients in the region. The four countries experienced a significant rise in AMR due to several factors during the COVID-19 pandemic, including an increase in hospital occupancy, a shift in priorities away from AMR surveillance, and changes in AMR epidemiology. Additionally, the large volumes of unnecessary and unsubstantiated antibiotic prescriptions during the COVID-19 pandemic has led to subsequent antibiotic shortages and significant increases in AMR in the region. Physicians also noted that the majority of COVID-19 patients were already on antibiotics before visiting the healthcare facility. MDR gram-negative bacteria were found in the majority of COVID-19 patients admitted to the intensive care unit. Despite the fact that various AMS initiatives have been implemented, they are not standardized across the region. Some of the main barriers to AMS implementation in the region are a lack of adequately trained AMS staff, lack of AMS knowledge and training among healthcare professionals, financial constraints, and the lack of AMR surveillance systems.

Conclusion

These survey results provide valuable insights into the existing AMR and AMS landscape in the region, as well as the barriers that impede efficient AMS and AMR management. Based on these findings, the authors developed a call to action that suggests ways for each country in the region to address these challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCOVID-19AdultHumansChildEgyptCross-Sectional StudiesIraqJordanLebanonPandemicsDrug Resistance, BacterialSurveys and Questionnaires

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • National COVID-19 Vaccine Committee, American University of Beirut Medical Center, Beirut, Lebanon.
  • Critical Care Department, Cairo University, Giza, Egypt.
  • Pediatric Critical Care Units, Department of Pediatrics, Faculty of Medicine, Cairo University, Giza, Egypt.
  • School of Medicine, University of Jordan, Amman, Jordan.
  • Notre Dame des Secours University Hospital, Byblos, Lebanon.
  • Holy Spirit University of Kaslik, Byblos, Lebanon.

ORCID-Profile: Jamal Wadi Al Ramahi, Madonna Matar

Förderung

  • Pfizer Inc

Zitieren

APA

Bizri, A. R., El-Fattah, A. A., Bazaraa, H. M., Al Ramahi, J. W., Matar, M., Ali, R. A. N., El Masry, R., Moussa, J., Abbas, A. J. A., & Aziz, M. A. (2023). Antimicrobial resistance landscape and COVID-19 impact in Egypt, Iraq, Jordan, and Lebanon: A survey-based study and expert opinion. PLOS ONE. https://doi.org/10.1371/journal.pone.0288550

Vancouver

Bizri AR, El-Fattah AA, Bazaraa HM, Al Ramahi JW, Matar M, Ali RAN, et al. Antimicrobial resistance landscape and COVID-19 impact in Egypt, Iraq, Jordan, and Lebanon: A survey-based study and expert opinion. PLOS ONE. 2023. doi:10.1371/journal.pone.0288550

BibTeX
@article{Bizri2023,
  author = {Bizri, Abdul Rahman and El-Fattah, Alia Abd and Bazaraa, Hafez Mahmoud and Al Ramahi, Jamal Wadi and Matar, Madonna and Ali, Rana Abdulmahdi Nahi and El Masry, Rowan and Moussa, Jihane and Abbas, Ali Jamal Al and Aziz, Mohamed Abdel},
  title = {Antimicrobial resistance landscape and COVID-19 impact in Egypt, Iraq, Jordan, and Lebanon: A survey-based study and expert opinion},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0288550}
}
Kostenlos starten →